Last 31 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 5.27 | — | — | 0.64 | — | — | — | — | 31.87 | — | — | 4.50 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.50 | 19.46 | 23.14 | 0.54 | 18.18 | 33.11 | 14.75 | 23.28 | 2.37 | 5.61 | 22.56 | 1.31 | — | — | — | 2.07 | — | — | 126.62 | — | — |
| — | -41.2% | +56.9% | -97.7% | +666.3% | +490.1% | -34.6% | +1680.0% | — | — | — | -36.7% | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.79 | 2.28 | 2.11 | 1.41 | 3.14 | 3.31 | 2.36 | 2.49 | 2.69 | 2.58 | 3.87 | 2.67 | 1.54 | 1.60 | 0.88 | 0.80 | 0.71 | 3.44 | 8.46 | 10.62 | 9.43 |
| — | -31.1% | -10.5% | -43.5% | +16.7% | +28.5% | -39.0% | -6.6% | +74.2% | +60.8% | +340.4% | +234.6% | +116.4% | -53.4% | -89.6% | -92.5% | -92.4% | -67.3% | +13.9% | +206.2% | +120.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 2.77 | — | — | 0.25 | — | — | — | — | 6.85 | — | — | 2.25 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 3.12 | — | — | 0.25 | — | — | — | — | 6.85 | — | — | 2.17 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.3% | -3.5% | 16.2% | 94.7% | 12.7% | -32.5% | -5.1% | 54.1% | 79.0% | 76.8% | 17.9% | 94.0% | — | — | — | 87.0% | — | — | 97.0% | — | — |
| — | +89.1% | +418.5% | +75.1% | -83.9% | -142.2% | -128.4% | -42.4% | — | — | — | +8.1% | — | — | — | — | — | — | — | — | — | |
| Operating Margin | 43.1% | -339.6% | -414.4% | 83.2% | -417.4% | -670.6% | -367.6% | -508.7% | 26.2% | -50.9% | -331.8% | 53.7% | — | — | — | -47.1% | — | — | -454.5% | — | — |
| — | +49.4% | -12.7% | +116.4% | -1690.5% | -1217.2% | -10.8% | -1046.4% | — | — | — | +214.2% | — | — | — | — | — | — | — | — | — | |
| Net Margin | 48.6% | -269.3% | -352.4% | 84.4% | -369.1% | -584.1% | -314.4% | -415.8% | 7.4% | -31.7% | -284.0% | 29.0% | — | — | — | -41.2% | — | — | -428.2% | — | — |
| — | +53.9% | -12.1% | +120.3% | -5055.1% | -1743.9% | -10.7% | -1532.5% | — | — | — | +170.4% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 44.8% | -7.6% | -7.7% | 77.6% | -14.8% | -13.7% | -12.8% | -10.6% | 2.1% | -3.6% | -11.6% | 16.4% | -17.1% | -14.1% | -12.7% | -3.9% | -12.6% | -7.6% | -6.9% | -6.0% | -7.4% |
| — | +44.3% | +39.6% | +831.7% | -790.8% | -280.1% | -10.5% | -164.8% | +112.6% | +74.6% | +8.7% | +516.5% | -35.7% | -85.2% | -83.4% | +35.1% | -69.2% | +58.6% | +60.0% | +75.0% | +74.5% | |
| ROA | 26.0% | -4.9% | -5.1% | 44.7% | -6.8% | -6.6% | -6.2% | -5.1% | 1.1% | -1.9% | -6.2% | 10.3% | -13.6% | -11.5% | -10.5% | -3.2% | -10.1% | -6.4% | -6.1% | -5.4% | -6.3% |
| — | +25.5% | +18.6% | +971.2% | -725.4% | -248.8% | -0.8% | -149.9% | +108.0% | +83.5% | +40.9% | +421.8% | -34.2% | -79.8% | -72.1% | +40.5% | -62.2% | +49.5% | +48.4% | +70.3% | +72.4% | |
| ROIC | 85.9% | -7.9% | -13.4% | 154.5% | -13.8% | -13.7% | -14.8% | -11.7% | 6.4% | -11.8% | -27.2% | 45.1% | -29.9% | -35.5% | -23.3% | -8.5% | -19.2% | -6.1% | -12.0% | -10.5% | -8.6% |
| — | +42.3% | +9.7% | +1418.9% | -315.6% | -16.0% | +45.5% | -126.0% | +121.4% | +66.6% | -16.9% | +628.8% | -55.2% | -485.3% | -93.7% | +18.6% | -123.7% | +82.5% | +74.2% | +84.3% | +83.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.07 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.03 |
| — | -42.4% | -36.6% | -45.7% | +37.9% | +13.8% | -7.3% | +157.3% | +84.0% | +101.1% | +102.6% | -16.8% | +6.9% | +0.2% | -2.2% | -0.5% | -3.0% | -72.4% | -82.2% | — | — | |
| Debt / EBITDA | 0.09 | — | — | 0.05 | — | — | — | — | 0.51 | — | — | 0.07 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.56 | 5.72 | 6.23 | 6.56 | 4.38 | 4.74 | 5.09 | 5.26 | 4.14 | 4.12 | 4.29 | 4.36 | 5.81 | 6.43 | 7.13 | 7.23 | 6.16 | 7.21 | 12.27 | 16.93 | 17.01 |
| — | +20.5% | +22.3% | +24.7% | +6.0% | +15.0% | +18.8% | +20.5% | -28.8% | -35.8% | -39.9% | -39.6% | -5.8% | -10.9% | -41.9% | -57.3% | -63.8% | +9.2% | +128.0% | +263.1% | +187.4% | |
| Quick Ratio | 6.56 | 5.72 | 6.23 | 6.56 | 4.38 | 4.74 | 5.09 | 5.26 | 4.14 | 4.12 | 4.29 | 4.36 | 5.81 | 6.43 | 7.13 | 7.23 | 6.16 | 7.21 | 12.27 | 16.93 | 17.01 |
| — | +20.5% | +22.3% | +24.7% | +6.0% | +15.0% | +18.8% | +20.5% | -28.8% | -35.8% | -39.9% | -39.6% | -5.8% | -10.9% | -41.9% | -57.3% | -63.8% | +9.2% | +128.0% | +253.0% | +187.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 31 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CGEN stock.
Compugen Ltd.'s current P/E is 5.3x. The average P/E over the last 1 quarters is 0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Compugen Ltd.'s current operating margin is 43.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Compugen Ltd.'s business trajectory between earnings reports.